Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The WWTR1 (protein is known as TAZ)-CAMTA1 (WC) fusion gene defines epithelioid hemangioendothelioma, a malignant vascular cancer. TAZ (transcriptional coactivator with PDZ binding motif) is a transcriptional coactivator and end effector of the Hippo tumor suppressor pathway. It is inhibited by phosphorylation by the Hippo kinases LATS1 and LATS2. Such phosphorylation causes cytoplasmic localization, 14-3-3 protein binding and the phorphorylation of a terminal phosphodegron promotes ubiquitin-dependent degradation (the phosphorylation of the different motifs has several effects). CAMTA1 is a putative tumor suppressive transcription factor. Here we demonstrate that TAZ-CAMTA1 (TC) fusion results in its nuclear localization and constitutive activation. Consequently, cells expressing TC display a TAZ-like transcriptional program that causes resistance to anoikis and oncogenic transformation. Our findings elucidate the mechanistic basis of TC oncogenic properties, highlight that TC is an important model to understand how the Hippo pathway can be inhibited in cancer, and provide approaches for targeting this chimeric protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
Justice, R. W., Zilian, O., Woods, D. F., Noll, M., & Bryant, P. J. (1995) · Genes & Development · doi:10.1101/gad.9.5.534 · Cited by 977
Xu, T., Wang, W., Zhang, S., Stewart, R. A., & Yu, W. (1995) · Development · doi:10.1242/dev.121.4.1053 · Cited by 799
Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway
Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C., & Halder, G. (2003) · Nature Cell Biology · doi:10.1038/ncb1050 · Cited by 747
Liu, C.-Y., Zha, Z.-Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., Chan, S. W., Lim, C. J., Hong, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152942 · Cited by 525
Tremblay, A. M., Missiaglia, E., Galli, G. G., Hettmer, S., Urcia, R., Carrara, M., Judson, R. N., Thway, K., Nadal, G., Selfe, J. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.029 · Cited by 178
Cited by
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
“(EisingerMathason et al., 2015) IHC: elevated nuclear YAP staining in human UPS samples (EisingerMathason et al., 2015) IHC: elevated nuclear YAP staining in sarcomas arising by targeted activation of oncogenic KRas and loss of p53 in fibroblasts (EisingerMathason et al., 2015) YAP knockdown impairs the growth of subc…”
BackgroundInfluentialTargeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 420
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Self-citationTAZ and YAP are frequently activated oncoproteins in sarcomas
Fullenkamp, C. A., Hall, S. L., Jaber, O. I., Pakalniskis, B. L., Savage, E. C., Savage, J. M., Ofori-Amanfo, G. K., Lambertz, A. M., Ivins, S. D., Stipp, C. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8979 · Cited by 78
Self-citationRequirement for YAP1 signaling in myxoid liposarcoma
Trautmann, M., Cheng, Y., Jensen, P., Azoitei, N., Brunner, I., Hüllein, J., Slabicki, M., Isfort, I., Cyra, M., Berthold, R., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809889 · Cited by 32
“Beyond that, aberrant Hippo signaling can arise from chromosomal translocations involving YAP1 or WWTR1 (encoding TAZ) as in epithelioid hemangioendothelioma, another fusion gene-driven soft-tissue tumor (Errani et al, 2011; Tanas et al, 2011, 2016; Antonescu et al, 2013).”
Background
Metadata
- Authors
- Tanas, M. R., Ma, S., Jadaan, F. O., Ng, C. K. Y., Weigelt, B., Reis-Filho, J. S., & Rubin, B. P.
- Venue
- Oncogene
- Published
- 2015-05-11
- Volume
- 35
- Issue
- 7
- Pages
- 929-938
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W233051009
- Cited by
- 113
- References
- 8
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.